Rheumatology Podcast Archive 2009-2019
Explore the archive from Rheumatology and Rheumatology Advances in Practice below.
Browse the archive from 2020-2022 here.
Rheumatology Podcast Archive
2019 || 2018 || 2017 || 2016 || 2015 || 2014 || 2013 || 2012 || 2011 || 2010 || 2009
2019
Dr Matthew J. Koster On The Diagnosis, Monitoring and Management of Large-Vessel GCA... April 2019
Dr James Galloway talks to Dr Matthew J. Koster, Mayo Clinic, Minnesota, USA, about his paper on the diagnosis, monitoring and management of large-vessel giant cell arteritis (GCA), which was published as part of our GCA supplement back in February, 2018. Dr Koster talks about how he initially developed an interest in GCA, before discussing the clinical challenges and recommendations highlighted within this review.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Large-vessel giant cell arteritis: diagnosis, monitoring and management
Wolfgang Schmidt On the Use of Ultrasound in Diagnosing and Managing Giant Cell Arteritis (GCA)... March 2019
Digital and Co-Editor Dr James Galloway interviews Prof. Dr. med. Wolfgang Schmidt (Immanuel Krankenhaus Berlin, Germany) about his review on the use of ultrasound in diagnosing and managing giant cell arteritis (GCA). They discuss the importance of further clinical investigation when dealing with possible cases of GCA, as well as the benefits and challenges of using MRI and PET scans. Prof. Schmidt’s review was published in February 2018.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice
Dr Laura Cappelli on Shared Epitope Alleles and Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis... March 2019
Editor-in-Chief Dr Marwan Bukhari interviews Dr Laura Cappelli (Johns Hopkins University, USA) about her recent paper, which examines the frequency of shared epitope (SE) alleles in patients with immune checkpoint inhibitor-induced inflammatory arthritis. The study found that over 60% of these patients possessed at least one SE allele, and included comparisons to both rheumatoid arthritis patients and healthy controls. This paper is the Editor’s Choice for March 2019.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis
Dr Sujith Subesinghe on Biologic Prescribing Decisions Following Serious Infection in RA Patients... February 2019
Dr James Galloway talks to Dr Sujith Subesinghe, Kings College London, about his recent paper which looked at biologic prescribing decisions following serious infection in RA patients. Analyses of data from the British Society for Rheumatology Biologics Register showed that patients who continued or switched their TNFi post-index SI had a lower risk of recurrent SI infection compared with those who stopped the drug. Reasons for this are discussed, and the clinical implications of the findings are highlighted.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register—Rheumatoid Arthritis
Dr Chris Holroyd on the Updated BSR Biologic DMARD Safety Guidelines in Inflammatory Arthritis... February 2019
Dr James Galloway talks to Dr Chris Holroyd, consultant rheumatologist at University Hospital Southampton, UK, about the new and updated BSR biologic DMARD safety guidelines in inflammatory arthritis. This guideline provides updates on screening before commencing a biologic, particularly the requirement for every patient to be screened for tuberculosis, using a tuberculin skin test (TST) or IFN-γ release assay (IGRA). In addition, there are changes for vaccination requirements before starting a biologic, and what to do before surgery.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis
Dr Vanessa Smith on Simple Capillaroscopic Definitions to Describe Capillary Morphology... January 2019
Dr Vanessa Smith, Ghent University Hospital, Belgium, and Dr Marwan Bukhari discusses Dr Smith's paper which proposed simple capillaroscopic definitions to describe capillary morphology. Currently different definitions are used for single capillaries across studies; these definitions would allow a common language in the literature. The study, carried out on behalf of the EULAR study group on microcirculation, demonstrated the definitions are reliable for evaluating capillary abnormalities.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases
Marwan Bukhari and Associate Editor, Xenofon Baraliakos, On What He Looks For In A Paper... January 2019
Recorded at the ACR Congress 2018 in Chicago, USA, our incoming Editor-in-Chief Marwan Bukhari, talks to our Associate Editor Xenofon Baraliakos (Consultant and Head of the Rheumazentrum Ruhrgebiet at Ruhr-University Bochum in Germany). Referring to his expertise within spondlyoarthritides, Xenofon tells us what he looks for in a paper. Novelty, impact on daily practice and the application of data that can change and improve every day clinical practice are key areas that should not be overlooked in a paper.
To listen to the podcast click below:
2018
Dr Andrew Filer On The Role Of Ultrasound-Defined Tenosynovitis... December 2018
Dr Marwan Bukhari interviews Dr Andrew Filer, University of Birmingham, UK, about his recent paper on the role of ultrasound-defined tenosynovitis and synovitis in the prediction of RA development. The study showed that using ultrasound to scan the flexor tendons in the hands are useful in predicting the development of RA in patients with early arthritis.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
The role of ultrasound-defined tenosynovitis and synovitis in the prediction of rheumatoid arthritis development
Dr Susan Goodman On Management Of Perioperative TNFΑ Inhibitors... November 2018
Dr Marwan Bukhari talks to Dr Susan Goodman, Weill Cornell Medical College, New York, USA, about her paper on management of perioperative TNFα inhibitors in RA patients undergoing arthroplasty. Evidence from the literature suggests an increase in surgical site infections in patients either currently or recently using TNF inhibitors. They discuss the need for these findings to be confirmed by prospective studies in the context of other infection risks such as higher disease activity, corticosteroid use, smoking and diabetes.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis
Dr Faith Matcham On The Relationship Between Depression and Biologic Treatment Response in Rheumatoid Arthritis... October 2018
Dr Faith Matcham, King’s College London, UK, discusses her recent paper on the relationship between depression and biologic treatment response in rheumatoid arthritis with Dr James Galloway. Analysis of data from the British Society for Rheumatology Biologics Register showed patients who reported symptoms of depression at baseline had a reduced likelihood of having a good treatment response and a much-reduced improvement in disease activity at 1-year follow-up. They discussed the importance of considering mental health comorbidity when treating patients.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis
Prof Raphaèle Seror On Smoking Status and the Risk of Incident RA... September 2018
Prof Raphaèle Seror, Université Paris, France and Dr Marwan Bukhari discuss the recently published study investigating the link between smoking status and the risk of incident RA. The study found that passive exposure to smoking in childhood may increase the risk of RA in future light and non-smokers. Prof Seror highlights the importance of ensuring a tobacco free environment for children, especially when a family history of RA is present.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Passive smoking in childhood increases the risk of developing rheumatoid arthritis
Dr John Hanly on Lupus Nephritis... September 2018
Dr Marwan Bukhari and Dr John Hanly, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Canada, talk about his paper on the frequency and outcome of lupus nephritis in a prospective SLE inception cohort. In the SLICC inception cohort study, 38% percent of patients developed lupus nephritis within the first 5 years of disease, with 10% of these developing end stage renal disease at 10 year follow-up.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
The frequency and outcome of lupus nephritis: results from an international inception cohort study
Dr Edward Roddy On the Recently Conducted Gout Audit… August 2018
Dr Marwan Bukhari and Dr Edward Roddy, Keele University, UK, talk about the recently conducted gout audit. In this, data from 91 UK rheumatology departments was collected, assessing on the concordance of gout management with evidence-based best-practice recommendations. Dr Roddy states the audit found most areas of gout management concorded well with guidelines for treatment, with treat to target being the main area with shortfalls. He highlights the importance of increasing efforts to achieve treat to target recommendations to improve gout patients’ quality of life.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Management of gout by UK rheumatologists: a British Society for Rheumatology national audit
Prof. Yoshiya Tanaka On Strategic Treatment of Psoriatic Arthritis Patients… July 2018
Dr Marwan Bukhari speaks to Professor Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, about his recent paper on strategic treatment of PsA patients according to phenotypic differences in helper T cells. They highlight the benefits of using precision medicine to treat PsA, with significantly higher efficacy observed in this study than in standard bDMARD therapy. They discuss the potential next steps for precision medicine in other diseases and new drugs becoming available for treatment.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis
Prof. Jacques Morel On Risk Factors of Serious Infections In Patients with RA ... APRIL 2018
Professor Jaap van Laar interviews Professor Jacques Morel, University of Montpellier, regarding his study on risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE
Dr Karl Gaffney On the BSR and BHPR Guideline for the Treatment of Axial Spondyloarthritis ... March 2018
Professor Jaap van Laar talk to Dr Karl Gaffney, Norwich University Hospital, regarding his work on updated BSR and BHPR guidelines for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics
Dr Helena Andersson On Long-Term Experience with Rituximab ... Feb 2018
Professor Jaap van Laar interviews Dr Helena Andersson, Oslo University, regarding her study on long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease
Colour Duplex Sonography in the Routine Care of GCA ... Jan 2018
Dr Andreas Diamantopoulos, Martina Hansens Hospital, Olso speaks to Dr Marwan Bukhari about his recently published paper on the use of colour duplex sonography in the routine care of GCA. They discuss the benefits of using of ultrasound in clinical diagnosis of GCA for early diagnosis and how this could be implemented in clinics.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice
2017
Short-term Efficacy and Safety of Rituximab Therapy in Refractory Systemic Lupus Erythematosus ... Dec 2017
Dr Marwan Bukhari and Prof Ian Bruce, University of Manchester, talk about his recently published paper on the results of the use of rituximab to treat refractory SLE from the BILAG biologics register. Prof Bruce is the chief investigator of the register, which observes patients going onto biologics for active disease. The focus of the study was to monitor the use of rituximab in SLE patients and gather real world evidence on the safety and efficacy of this. The study found that after 6 months of treatment 49% of patients showed a measurable response to treatment with rituximab, similar to what was observed in clinical trials.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
BSR Guideline for the Management of Systemic Lupus Erythematosus in Adults ... Oct 2017
Dr Marwan Bukhari and Prof Caroline Gordon, University of Birmingham, UK, discuss the recently published BSR guideline for the management of SLE in adults, the first guideline on the treatment of this condition. They discuss the evidence base for the guideline and recommendations for the diagnosis and treatment of patients with SLE.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
Muscle Mass Relative to Fat Mass with Physical Function in RA ... Sept 2017
Dr Marwan Bukhari talks to Prof Jon Giles, Columbia University, New York, USA, regarding his paper on the associations of muscle mass relative to fat mass with physical function in RA. Prof Giles states both his and his co-authors past research indicates that body composition, low muscle and high fat, is very strongly associated with physical function and, in some cases, more strongly associated with physical dysfunction thank the number of swollen and tender joints a patient has. He highlights the importance of considering muscle and fat mass impact on patients to improve physical function. They discuss the next steps to be taken to build on this research.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Assessment of muscle mass relative to fat mass and associations with physical functioning in rheumatoid arthritis
Twitter, #AlternativeFacts, Careless Whispers and Rheumatology ... June 2017
Prof Jaap van Laar, Editor of Rheumatology, and Associate Editors Dr James Galloway (King’s College London) and Dr Marwan Bukhari (University Hospitals of Morecambe Bay Foundation NHS trust) discuss the impact of social media on science. The rise of social media as a method of news consumption has created a society that wants convenient, succinct information. Subtle changes in the way information is conveyed are amplified the further down the chain you get, as evidenced recently when a paper’s meaning became lost within social media. The rise of alternative metrics to measure impact has also led to success and infamy being measured in equal manner.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Twitter, #alternativefacts, careless whispers and Rheumatology
BSR Guideline for the Management of Gout ... June 2017
Prof Jaap van Laar talks to Dr Ed Roddy, Keele University, UK, about the recently published update of the BSR guideline for the management of gout. Dr Roddy explains the need for this update due to the development of new drugs to treat gout as well as epidemiological studies showing an increase of incidence and prevalence but a lack of improvement in the treatment of gout. The guideline highlights the importance of increasing both GP and patient education. It also suggests a paradigm shift in the treatment to using urate lowering drugs in all patients and not waiting until a chronic condition develops.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
The British Society for Rheumatology Guideline for the Management of Gout
BSR and BHPR Guideline for the Prescription and Monitoring of Non-Biologic DMARDS ... June 2017
Prof van Laar and Dr James Galloway, King’s College London, UK, talk about the BSR guideline for the prescription and monitoring of non-biologic DMARDs. Dr Galloway explains the need for this update of existing guidelines due development of new drugs and previous treatments no longer being used. He highlights the headline changes from the previous guideline and discusses one of the more controversial recommendations made.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs
Management of Sjögren's Syndrome ... June 2017
Prof Jaap van Laar talks to Dr Elizabeth Price, Great Western Hospital NHS Foundation Trust, UK, about the BSR guidelines the management of Sjögren’s syndrome. Dr Price explains the development of the guidelines with specials across rheumatology, oral medicine and ophthalmology as well as occupational therapists and patient representatives to produce a particle guide for the management of Sjörgren’s that can be used across disciplines. The aim of the guideline is to allow early detection and treatment using a holistic and personalised approach to improve the patient’s current condition and long term prognosis.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Management of Sjögren's Syndrome
The Influence of Obesity on Response to Tumour Necrosis Factor-Α Inhibitors in Psoriatic Arthritis: Results from the DANBIO AND ICEBIO Registries... March 2017
Professor Jaap van Laar interviews Dr Lars Eric Kristensen, Parker Institute, Copenhagen, Denmark, regarding his paper on the link between obesity and biological use in psoriatic arthritis. The observational cohort study uses nationwide data from the DANBIO and ICEBIO registries.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries
Analysis of Extended Follow-Up Data from the Interferon Α Kinoid Phase I/II Study … March 2017
Professor Jaap van Laar interviews Dr Bernard Lauwerys, UCLouvain, Belgium, regarding his study on interferon α kinoids and their effect on B cell activation transcripts in Lupus. The paper discusses the link between the blockade of interferon α and the decreased expression of genes involved in B cell activation.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study
Gender Differences in Ankylosing Spondylitis ... - February 2017
Professor Jaap van Laar interviews Dr Astrid van Tubergen, Maastricht University, The Netherlands, regarding her study on gender differences in ankylosing spondylitis. The paper focuses on clinical and radiographic outcomes, using 12 years of follow-up data from the OASIS cohort.
To listen to the podcast click below:
Click on the following link to read the related paper for free:
Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
2016
RA Patient Access to DMARDS in Norway ... - September 2016
Dr James Galloway and Dr Samantha Hider, Keele University, UK discuss a paper by Polina Putrik et al. which looked at access to DMARDs. They discuss the findings of the paper which demonstrated that older patients with low levels of education have less access to DMARDs. They also explore the possible implications of these findings on the daily practice of rheumatologists and the importance of looking at health literacy of patients in practice.
To listen to the podcast click below:
RA patient access to DMARDs in Norway
Click on the following link to read the related paper for free:
Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD
Treating IGG4-Related Disease with Rituximab ... September 2016
Dr James Galloway and Dr Justin Mason, Imperial College London, UK discuss a paper published in the Journal by John Stone et al. who looked at patients with IgG4 related disease treated with rituximab, to determine if there were potential markers to predict relapse in patients after treatment. They discuss the potential implications for future treatment, drawbacks of the study and possible future research directions for the disease.
To listen to the podcast click below:
Treating IgG4-related disease with rituximab
Click on the following link to read the related paper for free:
Predictors of disease relapse in IgG4-related disease following rituximab
BSR Guidelines on Axial Spondyloarthritis … September 2016
Dr James Galloway and Dr Louise Hamilton, Norfolk and Norwich University Hospital, UK discuss the key findings of the updated BSR guidelines on axial spondyloarthritis and recommendations for treatment. They highlight the importance of considering extra-articular manifestations in treatment and the possibility of switching treatment if anti-TNF treatment fails.
To listen to the podcast click below:
BSR guidelines on axial spondyloarthritis
Click on the following link to read the related paper for free:
BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics
Guidance for the Treatment of Systemic Sclerosis … July 2016
Dr Marwan Bukhari and Prof Christopher Denton, University College London, London, UK, discuss the new BSR and BHPR guidelines for the management of scleroderma and systemic sclerosis. They discuss the key recommendations of these guidelines and the importance of proper patient assessment to provide the correct management for each affected individual.
To listen to the podcast click below:
Guidance for the treatment of systemic sclerosis
Click on the following link to read the related paper for free:
BSR and BHPR guideline for the treatment of systemic sclerosis
Guidance on Prescribing Drugs in Pregnancy... - May 2016
Dr Marwan Bukhari and Dr Ian Giles (University College London Hospital, UK) discuss the treatment of rheumatic problems in relation to pregnancy and the BSR and BHPR guideline on prescribing drugs during pregnancy. They discuss the key findings and recommendations presented in the guideline.
To listen to the podcast click below:
Guidance on prescribing drugs in pregnancy and breastfeeding
Click on the following links to read the related papers for free:
- BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids
- BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part II: analgesics and other drugs used in rheumatology practice
Relapse and Treatment Outcomes in Biopsy-Proven ... - March 2016
Prof Jaap van Laar, Editor of Rheumatology and Dr Eric Matteson, Mayo Clinic, Rochester, USA discuss the study about the level of dosing of corticosteroids in giant cell arthritis in their retrospective cohort study over a 15-year period. They talk about the rationale for this study, their key observations, why some patients relapse and why some patients need to be treated longer than others, or suffer more from side effects due to long steroid exposure. Dr Matteson talks about the findings from this study and surmises that actually it might be better to start with a higher dose in the first place.
To listen to the podcast click below:
Relapse and treatment outcomes in biopsy-proven giant cell arteritis
Click on the following link to read the related paper for free:
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study
Effect of Allopurinol on All-Cause Mortality in Adults ... - February 2016
Professor Michael Doherty from the University of Nottingham, Nottingham, UK, speaks to Prof Jaap van Laar, Editor of Rheumatology about their study published in the Journal. The questions they discussed were around when allopurinol is given to patients, effective dosage of allopurinol, which is often not correct, and helping GPs treat to target.
Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score–matched landmark analysis
Click on the following link to read the related paper for free:
Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score–matched landmark analysis
2015
Fast-Track Ultrasound Clinic for Early Diagnosis of GCA - December 2015
Dr Marwan Bukhari, Dr Andreas Diamantopoulos, Hospital of Southern Norway Trust and Dr Christian Dejaco, Medical University Graz, discuss giant cell arteritis and visual impairment. They review a paper by Andreas Diamantopoulos et al. which presents the advantages of a fast-track ultrasound clinic in the early diagnosis and treatment of GCA related blindness and discuss potential limitations of the study and implications for clinical practice.
To listen to the podcast click below:
Fast-track ultrasound clinic for early diagnosis of GCA
Click on the following link to read the related paper for free:
The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?
2014
Vasculitis Associated with RA - July 2014
Dr Marwan Bukhari, The University Hospitals of Morecambe Bay NHS Foundation Trust, and Dr James Galloway, King’s College London, review a paper by Ashima Makol et al. that evaluates risk factors and clinical outcomes of vasculitis associated with rheumatoid arthritis. They discuss some surprising predictors of the co-morbidity and the limitations of this study, and suggest possible targets for future research.
To listen to the podcast, click below:
Vasculitis associated with RA
Click on the following link to read the related paper for free:
Vasculitis associated with rheumatoid arthritis: a case–control study
Change at the Top - February 2014
Professor Robert Moots and Professor Jaap van Laar (University Medical Cente Utrecht, Netherlands) discuss Professor Moots’ time as Editor, his achievements over the past 5 years and the changes that have occurred in the publishing industry. This is Professor Moots’ last podcast in charge of the Journal as he hands over the reins of Rheumatology to Professor Jaap van Laar as the new Editor of the Journal.
To listen to the podcast, click below:
Change at the top
Treatment for Antiphospholipid Antibodies - January 2014
Professor Robert Moots and Dr Chris Edwards (Southampton General Hospital, UK) discuss antiphospholipid antibody syndrome and the problems encountered with this disorder. They examine a paper by Maria J. Cuadrado et al on the efficacy and safety of low-dose aspirin in patients positive for antiphospholipid antibodies, discussing the problems of treatment and how the study translates for everyday practice.
To listen to the podcast, click below:
Treatment for antiphospholipid antibodies
Click on the following link to read the related paper for free:
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)
The Evolution of RA Treatment: Will We Find The Cure? - Jan 2014
Professor Robert Moots, Professor Josef Smolen, University of Vienna, Austria, and Professor Emilio Martín-Mola, Hospital Universitario La Paz, Madrid, Spain, praise the advances in treatment of RA over the past thirty years and debate how best to translate these advances into clinical practice to address the unmet needs within the field.
To listen to the podcast, click below:
The evolution of RA treatment: Will we find the cure?
2013
A New Kidney-Specific Diagnostic Marker To Assess Disease... - Dec 2013
Professor Robert Moots and Professor Bernard Lauwerys, Université catholique de Louvain, Brussels, discuss the complex nature of kidney disease in lupus nephritis as well as current and new diagnostic markers used to assess disease activity. They review a paper by Masanori Hanaoka et al that evaluates the use of urinary free light chains as a non-invasive kidney-specific biomarker for the response to treatment of lupus nephritis, and the potential association between the intensity of plasma cell infiltration of the kidney and urinary free light chain levels in the disease. They discuss the key findings as well as the limitations of this exploratory study.
To listen to the podcast, click below:
A new kidney-specific diagnostic marker to assess disease activity in lupus nephritis
Click on the following link to read the related paper for free:
Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis
Managing PatientS With Early RA - July 2013
Professor Robert Moots and Professor Zhanguo Li (People's Hospital, University of Beijing) discuss the challenges of managing patients with early rheumatoid arthritis and the new classification criteria. They discuss a paper by Krabben et al. on the risk of rheumatoid arthritis developments in patients with unclassified arthritis, debating the limitations of the study and the best way to treat patients.
To listen to the podcast, click below:
Managing patients with early RA
Click on the following link to read the related paper for free:
Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis
Systemic Sclerosis: Subsets and Diagnosis - July 2013
Professor Robert Moots and Professor Marco Matucci Cerinic (University of Florence, Florence, Italy) discuss systemic sclerosis providing an overview of the disease and the different subsets. They review a paper by Gonçalves Marangoni et al and discuss the importance of early diagnosis of systemic sclerosis sine scleroderma.
To listen to the podcast, click below:
Systemic sclerosis: subsets and diagnosis
Click on the following link to read the related paper for free:
Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort
New Molecules for the Treatment of Rheumatoid Arthritis - July 2013
Professor Robert Moots talks to Rheumatology co-Editor Roy Fleischmann (clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Dallas, USA) about the future of RA treatment. They discuss the review series on new molecules for the treatment of RA and ruminate on the next big development for RA treatment.
To listen to the podcast, click below:
New molecules for the treatment of rheumatoid arthritis
To read the editorial for the new molecules series for free click the following link:
Back to the future: oral small molecule kinases
The review articles for the series can be found here:
Novel small molecule therapeutics in rheumatoid arthritis - V Kelly and M Genovese
Small molecules targeting JAKs—a new approach in the treatment of rheumatoid arthritis - E Feist and G R. Burmester
Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis - J S Nijjar, A Tindell, I B McInnes & S Siebert
Epigenetics and Autoimmune Disease - July 2013
Professor Robert Moots and Dr Esteban Ballestar (Bellvitge Biomedical Research Institute [IDIBELL], Barcelona, Spain) discuss epigenetics and this field’s importance for autoimmune diseases. They review a paper by Cheng et al on decoy receptor 3‘s effect on RANK ligand-induced osteoclastogenesis. They discuss potential future developments and the limitations of the study.
To listen to the podcast, click below:
Epigenetics and autoimmune disease
Click on the following link to read the related paper for free:
Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis
Frequency of Anti-Infliximab Antibodies... - May 2013
Professor Robert Moots and Dr Steven Young (University of Birmingham School of Immunity and Infection), discuss the therapeutic role of antibodies given directly to patients and their response to these antibodies. They review a paper by Krentil et al. that reports the frequency of anti-infliximab antibodies in patients with RA, the associations with adverse drug reactions and treatment failure and the potential impact of the results of this study. They discuss why patients who initially respond well to TNF inhibitors may not do later, how this new protein chip process might help reduce cost of treatment and anxiety for patients, and whether this process could be applied to other biologic drugs.
To listen to the podcast, click below:
Frequency of anti-infliximab antibodies: patients with RA in routine care
Click on the following link to read the related paper for free:
The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure
Uric Acid-Lowering Therapy: Treatment of Gout - April 2013
Professor Robert Moots and Professor Pascal Richette from Lariboisière Hospital in France, discuss urate lowering therapy for the treatment of gout highlighting the issues that are encountered. They review a paper by Mitha et al on the use of rilonacept for gout flare preventionduring initiation of uric acid-lowering therapy with allopurinaol.
To listen to the podcast, click below:
Uric acid-lowering therapy: treatment of gout
Click on the following link to read the related paper for free:
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial
2012
Role of Patients in the Management of RA - Dec 2012
Professor Robert Moots and Professor Nemanja Damjanov, the Head of Institute of Rheumatology in Belgrade, discuss the role of patients in the management of RA and the implications this has for their treatment. They review a paper by Dougados et al on doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis. They discuss the key points and interesting outcomes of this paper as well as its limitations.
To listen to the podcast, click below:
Role of patients in the management of RA
Click on the following link to read the related paper for free:
Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study
Cardiovascular Risk in Ankylosing Spondylitis - Dec 2012
Professor Robert Moots and Professor Lai-Shan Tam from the Chinese University of Hong Kong, an expert in ankylosing spondylitis, discuss the risks for co-morbidities, highlighting cardiovascular disease, in ankylosing spondylitis and the potential mechanisms for such risks. They review a paper by Mathieu et al on arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment, speculating on the outcome of the study and its limitations as well as giving advice for clinicians treating ankylosing spondylitis patients.
To listen to the podcast, click below:
Cardiovascular risk in ankylosing spondylitis
Click on the following link to read the related paper for free:
No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months
MRI of Joints in Children - November 2012
Professor Robert Moots and Professor Helen Foster, University of Newcastle, discuss the difference of assessing children’s joints compared to adults and the challenges this present. They feature a paper by Von Kalle et al on contrast-enhanced MRI of normal temporomandibular joints in children, discussing the potentials and limitations of this study. What are the implications of this study to how MRIs are interpreted? Listen to the podcast and read the paper to find out more.
To listen to the podcast, click below:
MRI of joints in children
Click on the following link to read the related paper for free:
Contrast-enhanced MRI of normal temporomandibular joints in children—is there enhancement or not?
Keeping Pace with Changes in Vasculitis- August 2012
Professor R J Moots and Dr Richard Watts, previous editor of Rheumatology , discuss the major changes taking place in vasculitis, including the improved prognosis, and especially why stratifying patients is important. They examine whether the treatment approach for the different types of vasculitis should be the same – but what is the evidence? Does the aetiology differ for vasculitis in different populations? What are the challenges of splitting this group of diseases? Listen to the podcast for an understanding about the changes in the vasculitis community.
To listen to the podcast, click below:
Keeping pace with changes in vasculitis
Click on the following link to read the related paper for free:
ANCA vasculitis: to lump or split?: Why we should study MPA and GPA separately
Physical Activity in RA Patients - June 2012
Professor Robert Moots and Professor George Kitas, Dudley Group of Hospitals NHS Trust, discuss concerns in treating rheumatoid arthritis patients, focusing on physical activity. They look into the key findings of a paper on the physical activity and energy expenditure in rheumatoid arthritis patients by Henchoz et al. How does rheumatoid arthritis patients’ activity compare to controls, can physical activity benefit these patients?
To listen to the podcast, click below:
Physical activity in RA patients
Click on the following link to read the related paper for free:
Physical activity and energy expenditure in rheumatoid arthritis patients and matched controls
Evidence for Use of Complementary Medicine in RA - June 2012
Professor R Moots and Dr Marwan Bukhari, the Journal’s associate Editor as well as a consultant rheumatologist at Lancaster UK discuss about advising patients regarding alternative treatments or complementary therapy. They review the evidence from a paper published online in Rheumatology by Macfarlane et al. on a systematic review about the effectiveness of complementary therapy in the management of RA. What can a practicing clinician infer from this review and what should he or she advise their patient based on this review? To find out more, listen to the podcast.
To listen to the podcast, click below:
Evidence for use of complementary medicine in RA
Click on the following link to read the related paper for free:
Ultrasound Guided Steroid Injections in Children - May 2012
Professor Robert Moots and Dr Athimalaipet Ramanan from the Bristol Royal Hospital for Children, discuss the challenges of treating children with rheumatic diseases, focusing on joint injections. They feature Dr Ramanan’s paper on ultrasound guided steroid injections into temporomandibular joints in children with active JIA. They discuss the outcomes of the study and its limitations. Is ultrasound necessary to ensure patients are injected in the right place? Listen to the podcast and read the paper and make up your own mind.
To listen to the podcast, click below:
Ultrasound guided injections in children
Click on the following link to read the related paper for free:
Psoriatic Arthritis And a Placebo Controlled RCT - April 2012
Methotrexate in psoriatic arthritis - does it really work or are we just giving a placebo? Listen to Professor Robert Moots and Dr Robert Thompson, University of Liverpool discuss the management psoriatic arthritis and analyse a major new randomized placebo-controlled trial of MTX in PsA article recently published by G Kingsley et al. Will this change your practice?
To listen to the podcast, click below:
Psoriatic arthritis and a placebo controlled RCT
Click on the following link to read the related paper for free:
A randomized placebo-controlled trial of MTX in PsA
ANCA-Associated Vasculitis - March 2012
Professor Robert Moots and Dr Alfred Mahr discuss the challenges of ANCA-associated vasculitis, use of cyclophosphamide and granulomotosis with angiitis. They also discuss the use of rituximab particularly in light of the recommendations published by Guerry et al., how strong is the evidence base for these recommendations and how do these recommendations differ from Dr Mahr’s practice?
To listen to the podcast, click below:
ANCA-associated vasculitis
Click on the following link to read the related paper for free:
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis
BSR and BHPR Guidelines On The Use Of Rituximab - Feb 2012
How do you manage refractory rheumatoid arthritis? Listen to Professor Robert Moots, Editor, and Professor Paul Peter Tak from the University of Amsterdam, discuss advances in the treatment of RA and consider differences between clinical trials and real life clinical work. They also debate important new guidelines for the use of the rituximab in rheumatoid arthritis published in the Journal.
What is your view on this? Listen to the Podcast, look up the paper and make up your own mind.
To listen to the podcast click below:
Use of rituximab
Click on the following link to read the related paper for free:
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis
2011
Inflammatory Myopathies - June 2011
Professor Robert Moots and Dr Piet van Riel discuss the treatment of inflammatory myopathies and their efficacies in patients. They talk about a paper, on which Dr van Riel is a co-author, investigating the use of rituximab to treat refractory inflammatory myopathies. They look into the reasons behind the study and give advice for people looking after patients with inflammatory myopathies.
To listen to the podcast click below:
Inflammatory myopathies
Click on the following link to read the related paper for free:
Rituximab treatment in patients with refractory inflammatory myopathies
Early Rheumatoid Arthritis Treatment Strategies - June 2011
Professor Robert Moots and Professor Janet Pope talk about treatment strategies for early rheumatoid arthritis and the influence cost-effectiveness has. To further highlight the issues they discuss a paper by Schipper et al. comparing the cost-effectiveness of 3 different treatment strategies for patients with early RA.
To listen to the podcast click below:
Treatment strategies
Click on the following link to read the related paper for free:
Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective
Patient Perceptions - June 2011
Professor Robert Moots talks to Dr Fernando Cavalcanti about inflammatory arthritis and its treatment in Brazil, highlighting cultural differences in disease management and between patient and Doctor perceptions. They also discuss a review by Verschueren and Westhovens on the challenges of putting scientific treatment into clinical practice.
To listen to the podcast click below:
Patient perceptions
Click on the following link to read the related paper for free:
Optimal care for early RA patients: the challenge of translating scientific data into clinical practice
Cohorts in Rheumatoid Arthritis - May 2011
Professor Robert Moots and Professor Nancy Lane discuss a paper by Liao et al. about a rheumatoid arthritis cohort in Boston, USA. They talk about the use and importance of such cohorts and how they can inform treatment strategies and practices. They look into the strengths, limitations and challenges for linking bed-side observations to laboratory developments.
To listen to the podcast click below:
Rheumatoid arthritis cohorts
Click on the following link to read the related paper for free:
Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study
50TH Anniversary: A Perspective on the Past - March 2011
As part of the Journal’s 50th Anniversary celebrations Professor Robert Moots talks to Professor David GI Scott and Dr Michael Snaith about how the rheumatology field has changed over the past 60 years. They discuss treatment, therapeutic and practice developments and how a greater understanding of musculoskeletal disease has shaped these advancements.
To listen to the podcast click below:
A perspective on the past
Registries - January 2011
Professor Robert Moots and Professor David Isenberg discuss registries, what they are, their aims and outcomes. They highlight the British Society for Rheumatology Biologics Register, the largest biologics register in the world, detailing its design, aims and findings. Professor David Isenberg has been a guest Editor on the Journal’s themed issue on registries, a collection of papers on this topic.
To listen to the podcast click below:
Registries
2010
Is RA A Genetically Distinct Subset? - September 2010
Is rheumatoid arthritis a single disease or a group of related diseases? Professor Robert Moots and Professor Anthony Russell discuss this issue, probing into a paper by Ohmura et al published in Rheumatology. They discuss the key developments of this paper, what it means for treatment and its potential limitations.
To listen to the podcast click below:
Is rheumatoid arthritis a genetically distinct subset?
Click on the following link to read the related paper for free:
Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis
Thrombotic Events in SLE Patients - August 2010
The Editor Professor Robert Moots and Professor Mohammed Tikly, who is from the University of the Witwatersrand in South Africa, discuss a paper by Burgos et al about the complications of thrombic events in systemic lupus and the implications of this for clinical practice.
To listen to the podcast click below:
Factors predictive of thrombotic events in SLE patients
Click on the following link to read the related paper for free:
Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients
Spondyloarthropathies - July 2010
In this podcast Professor Robert Moots and Dr Dirk Elewaut discuss spondyloarthropathy diseases and their manifestations. They then go on to discuss a paper by Bruan et al. recently published in Rheumatology on the clinical manifestations of ankylosing spondylitis with and without concomitant psoriasis. They discuss the key issues the paper investigates and the study’s limitations.
To listen to the podcast click below:
Spondyloarthropathies: Ankylosing spondylitis with and without concomitant psoriasis - July 2010
Click on the following link to read the related paper for free:
Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis
Ferritin Levels and ILD in Dermatomyositis - May 2010
Can measurement of serum ferritin predict the development and severity of acute interstitial lung disease in dematomyositis? Professors Moots and Panayi delve into the paper by Gono et al who propose that the acute phase protein, ferritin, may represent a biomarker for complications in dermatomyositis.
To listen to their discussion about this study, issues the paper addressed and its limitations, please click link below.
Increase in ferritin levels and interstitial lung disease in dermatomyositis
Click on the following link to read the related paper for free:
Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis
Cost of Using TNF-Alpha Inhibitors - April 2010
What is the cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis? This paper, set in Finland, by Hallinen et al. is discussed by Professor Robert Moots and Dr. Ronald Frits van Vollenhoven. In the Podcast, they discuss current use of biologics, the effectiveness of TNF inhibitors, DMARDs and rituximab and consider whether the economic model used in this paper can effectively determine relative cost-effectiveness in a clinical setting.
Click on the link below to listen to this interview:
Cost of using TNF-alpha inhibitors
Click on the following link to read the related paper for free:
What is the cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis?
Cardiovascular Disease and Rheumatoid Arthritis - March 2010
An MRI study about understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation by Puntmann et al. is the paper for the discussion between Professor Robert Moots and Dr Christopher Edwards. Is there a link between cardiovascular diseases and RA, how does this association affect patients with RA and questions about this study are answered in this podcast.
Click on the link below to listen to this interview:
Cardiovascular disease and rheumatoid arthritis: what is the link?
Click on the following link to read the related paper for free:
An MRI study about understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation
Hypermobility in Children - February 2010
A randomized comparative trial of generalized vs targeted physiotherapy in the management of childhood hypermobility by Sue et al. published in Rheumatology is discussed by Robert Moots and Michael Beresford. What is childhood hypermobility and how does it present? Answers to these questions and discussions about the trial form the basis for this podcast.
Click on the link below to listen to this interview:
Hypermobility in children
Click on the following link to read the related paper for free:
A randomized comparative trial of generalized vs targeted physiotherapy in the management of childhood hypermobility
Treatment of Rheumatoid Arthritis with Biomarkers - Jan 2010
Robert Moots and Stephen Hall discuss the challenges in identifying biomarkers for selecting treatment and predicting adverse events in rheumatoid arthritis. They then discuss a paper by Quartuccio et al. investigating the utility of rheumatoid factor, anti-CCP antibodies and response to TNFi as potential predictors of response to rituximab in rheumatoid arthritis.
Click on the link below to listen to this interview:
The role of biomarkers in the treatment of rheumatoid arthritis
Click on the following link to read the related paper for free:
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis
2009
Rheumatoid Arthritis in Elderly Patients - December 2009
Is rheumatoid arthritis a homogeneous disease and can it be categorized by age? In our next podcast, Robert Moots with Daniel Solomon discusses not only these questions but also a study recently published by Rheumatology by Marcus Köller et al about the response of methotrexate or TNF inhibitors in elderly patients.
Click on the link below to listen to this interview:
Rheumatoid arthritis in elderly patients
Click on the following link to read the related paper for free:
Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients
Active Rheumatoid Arthritis - November 2009
In this podcast, Robert Moots and Roy Fleischmann discuss aspects of rheumatoid arthritis and concerns that patients commonly have about the disease. They then discuss a paper published in the Journal by Aslam Anis et al about the COMET study that examined the effect of etanercept on work productivity in patients with active rheumatoid arthritis.
Click on the link below to listen to this interview:
Active rheumatoid arthritis
Click on the following link to read the related paper for free:
The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study
Systemic Sclerosis - July 2009
Pulmonary complications of systemic sclerosis are amongst the most challenging to manage. In this podcast, Ulf Mueller-Ladner discusses the current management of these complications with Robert Moots and the potential for a new, more effective therapy using rituximab - in an article (Daoussis et al) recently published in Rheumatology.
Click on the link below to listen to this interview:
Systemic Sclerosis
Click on the following link to read the related paper for free:
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Antiphospholipid Antibody Syndrome - June 2009
In this first podcast from Rheumatology, Munther Khamashta (St Thomas’ Hospital London) and Anisur Rahman (University College London) discuss aspects of treatment of antiphospholipid antibody syndrome (APS) today and the potential for future therapy, in the context of recent advances in understanding the pathological processes that underlie this disease.
Click on the link below to listen to this interview:
Antiphospholipid Antibody Syndrome
The papers discussed in this podcast are available to read for free here:
